2TK Stock Chart & Stats
€3.36
-€0.10(-2.29%)
At close: 4:00 PM EST
€3.36
-€0.10(-2.29%)
Day’s Range― - ―
52-Week Range€1.17 - €3.70
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€279.19M
Enterprise Value€216.22M
Total Cash (Recent Filing)€111.09M
Total Debt (Recent Filing)€555.00K
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding77,187,820
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.57Price Target Upside125.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Durable Clinical Efficacy SignalLong-term BESTOW results showing sustained higher eGFR and absence of biopsy-proven acute rejection after six months indicate a durable clinical benefit in kidney transplant patients. Such durable graft function and lower rejection risk materially strengthen tegoprubart's differentiation, regulatory case, and long-term payer/hospital adoption prospects.
Very Low Financial LeverageExtremely low debt reduces financial distress risk and interest burden, giving the company flexibility to pursue clinical development over the multi-year horizon without immediate repayment pressures. This structural balance sheet strength supports continued R&D investment and makes future financing options less constrained by leverage limits.
Board And Audit StabilityRecent director elections and auditor ratification strengthen governance and oversight during pivotal clinical development. Stable board composition and reputable audit oversight improve strategic continuity, aid partnership and financing credibility, and support disciplined execution across the regulatory and commercialization planning phases.
Bears Say
No Product RevenueBeing pre-revenue means the company has no operating cash inflows from product sales, leaving its valuation and sustainability entirely tied to clinical progress and external funding. This structural absence of commercial revenue elevates execution and commercialization risk over the coming months until approval and launch.
Large, Persistent Cash BurnConsistently negative operating and free cash flow of roughly -$69M TTM creates recurrent financing needs. Persistent burn pressures strategic flexibility, increases dilution likelihood or dependence on costly financing, and can limit ability to scale trials or invest in commercialization capabilities absent partnerships or material capital raises.
Authorized Share Increase / Dilution RiskExpanded authorized shares improves capital-raising flexibility but signals likely future equity issuance, creating structural dilution risk for existing holders. Repeated equity financing to cover development burn can erode per-share economics and investor returns even if clinical milestones are met, affecting long-term shareholder value.
Eledon Pharmaceuticals News
2TK FAQ
What was Eledon Pharmaceuticals, Inc.’s price range in the past 12 months?
Eledon Pharmaceuticals, Inc. lowest stock price was €1.17 and its highest was €3.70 in the past 12 months.
What is Eledon Pharmaceuticals, Inc.’s market cap?
Eledon Pharmaceuticals, Inc.’s market cap is €279.19M.
When is Eledon Pharmaceuticals, Inc.’s upcoming earnings report date?
Eledon Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 25 days.
How were Eledon Pharmaceuticals, Inc.’s earnings last quarter?
Eledon Pharmaceuticals, Inc. released its earnings results on May 13, 2026. The company reported -€0.289 earnings per share for the quarter, missing the consensus estimate of -€0.161 by -€0.128.
Is Eledon Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Eledon Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Eledon Pharmaceuticals, Inc. pay dividends?
Eledon Pharmaceuticals, Inc. does not currently pay dividends.
What is Eledon Pharmaceuticals, Inc.’s EPS estimate?
Eledon Pharmaceuticals, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Eledon Pharmaceuticals, Inc. have?
Eledon Pharmaceuticals, Inc. has 77,187,820 shares outstanding.
What happened to Eledon Pharmaceuticals, Inc.’s price movement after its last earnings report?
Eledon Pharmaceuticals, Inc. reported an EPS of -€0.289 in its last earnings report, missing expectations of -€0.161. Following the earnings report the stock price went down -0.617%.
Which hedge fund is a major shareholder of Eledon Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in DE:2TK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eledon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€7.57 (125.41% Upside)
€7.57 (125.41% Upside)
Blogger Sentiment
Bullish
DE:2TK Sentiment 70%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.59%
12-Months-Change
Fundamentals
Return on Equity
-96.80%
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
2TK Stock 12 Month Forecast
Average Price Target
€7.57
▲(125.41% Upside)
Technical Analysis
Tvardi Therapeutics
―
Editas Medicine
―
Annexon Biosciences
―
Design Therapeutics
―
Tevogen Bio Holdings
―
Options Prices
Currently, No data available
---